Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.5 USD | +1.63% | -0.79% | -22.12% |
31/05 | Piper Sandler Starts Allogene Therapeutics With Overweight Rating, $11 Price Target | MT |
21/05 | Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.12% | 52Cr | |
+11.91% | 12TCr | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.12% | 2.2TCr | |
-9.35% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr |
- Stock Market
- Equities
- ALLO Stock
- News Allogene Therapeutics, Inc.
- Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating